Nerve Growth Factor Induces Cell Death In Some Childhood Tumors: Surprising Findings Suggest Cancer Gene Therapy Approach

January 15, 1997




During early development, the usual function of nerve growth factor (NGF) is to assist immature neuronal cells to survive and differentiate into a variety of nerve and brain tissues. Now, researchers at the University of Pennsylvania Medical Center have discovered that, paradoxically, NGF is also able to induce cells from a common type of childhood brain tumor called a medulloblastoma to undergo massive apoptosis, or cell suicide, when those cells have been engineered to express a receptor for NGF. A report on the study appears in the January 15 issue of The Journal of Neuroscience.

The surprising findings indicate that a gene therapy approach based on the mechanism might be useful in treating such cancers. Additionally, based on this and other studies, scientists may have to expand their understanding of the roles played by NGF and related biochemicals, also known as trophic or survival factors, in the development of the organism.

"One could say that these so-called growth factors have a dark side, too," observes Virginia M.-Y. Lee, PhD, a professor of pathology and laboratory medicine and senior author on the report. "They appear to be able to able to act in two directions, supporting the survival of cells or killing them depending on the stage of development."

NGF has been shown to serve a crucial purpose in helping early-stage neurons to thrive and reach their fully differentiated state, Lee explains. In fact, a number of investigators have conducted experiments showing that these cells die in the absence of NGF. In neural systems, however, it is also true that cells must cease to proliferate at a certain point, since mature nerve and brains cells are nondividing. So, the only neural cells that might continue to divide would be primitive, progenitor cell types or cancerous cells, neither of which should be present among most mature nerve or brain cell populations.

"Our study suggests that NGF may provide a single, needed mechanism by which dividing cells are killed while nondividing cells continue to differentiate," Lee says.

For their experiments, Lee and her colleagues infected two human medulloblastoma cell lines with a retroviral vector engineered to incorporate a gene that codes for the NGF-specific receptor. Cells thus infected subsequently expressed the receptor, referred to as TrkA, on their surfaces. Only about 25 percent of wild-type medulloblastoma cells naturally display the TrkA receptor.

Counter intuitively, the cancer cells underwent massive apoptosis when subsequently treated with NGF, a substance known to promote survival of neuronal progenitor cells and immature neurons of the central and peripheral nervous systems. Similar NGF-treatments of wild-type cells uninfected with the gene-bearing retroviral vector or cells infected with an empty vector did not induce cell suicide, and cells expressing other Trk-family receptors were likewise unaffected.


Yoshihiro Muragaki, MD, affiliated with both Penn and the Tokyo Women's Medical College, and Thomas T. Chou, BS, an MD-PhD student, are lead authors on the paper, having contributed equally to the work. John Q. Trojanowski, MD, PhD, a professor of pathology and laboratory medicine, is a coauthor, as is David R. Kaplan, PhD, formerly with the National Cancer Institute and now at McGill University in Montreal, Canada. Funding support was provided by the National Institutes of Health and the Alzheimer's Association.

Dr. Virginia M.-Y. Lee can be reached at (215) 662-6920.


The University of Pennsylvania Medical Center's sponsored research ranks fifth in the United States, based on grant support from the National Institutes of Health, the primary funder of biomedical research in the nation -- $140.5 million in federal fiscal year 1995. In addition, the institution posted the highest growth rate in its research activity -- 11.4 percent -- of the top ten U.S. academic medical centers during the same period. Penn news releases are available to reporters by direct e-mail, fax, or U.S. mail, upon request. They are also posted electronically to EurekAlert! (http://www.eurekalert.org), an Internet resource sponsored by the American Association for the Advancement of Science, and to the NASW (National Association of Science Writers) Online and SciNews-MedNews sections of the Journalism Forum, a component of CompuServe. Additionally, they are distributed via the electronic news service Quadnet.

University of Pennsylvania School of Medicine

Related Medulloblastoma Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Researchers find potential to make brain cancers in children respond better to treatment
Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies.

A promising new treatment for recurrent pediatric brain cancer
Researchers developed a novel approach that delivers appropriately-targeted chimeric antigen receptor (CAR) T cell therapy directly into the cerebrospinal fluid that surrounds recurrent pediatric brain tumors.

Inherited mutation can predispose children to a type of brain tumor
Collaboration co-led by researchers at St. Jude Children's Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.

Understanding brain tumors in children
The causes of 40% of all cases of certain medulloblastomas -- dangerous brain tumors affecting children -- are hereditary.

Targeting a transporter to treat SHH medulloblastoma
Scientists at St. Jude Children's Research Hospital have identified a novel target for a type of pediatric brain tumor.

Researchers identify novel potential combination therapy for childhood brain tumors
Brazilian researchers working in collaboration with Canadian scientists demonstrated that all medulloblastoma tumor subtypes express two stem cell markers: BMI1 and CD133.

Researchers identify possible approach to block medulloblastoma growth
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential approach to stop the growth of the most common type of brain tumor in children.

Leukemia drug shows promise for treating a childhood brain cancer
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.

Cracking the code of a brain cancer that keeps coming back
Researchers used a powerful new computer-assisted technology called single-cell transcriptomics that measures thousands of individual cells simultaneously to map cell types and molecular cascades that drive the growth of SHH-medulloblastoma.

Read More: Medulloblastoma News and Medulloblastoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.